Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05465954
Title Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Mayo Clinic
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST